FIELD: chemistry.
SUBSTANCE: invention relates to factor of fibroblasts 21 (FGF21) growth, in particular, to FGF21 derivatives, which have covalently connected albumin binding agent of formula A-B-C-D-E-, and their pharmaceutical application, in particular, for treatment of diabetes, dyslipidemia, obesity, cardio-vascular diseases, metabolic syndrome and/or non-alcoholic fatty disease of liver (NAFDL). Derivatives by claimed invention have prolonged action, for instance, are able to supply low level of glucose during longer period of time, are capable of increasing time of FGF21 semiejection in vivo and/or result in lower clearance of FGF21.
EFFECT: derivatives by invention preferably have improved resistance to oxidation.
10 cl, 4 tbl, 58 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LONG-ACTING AGONISTS OF RECEPTORS Y2 AND(OR) Y4 | 2009 |
|
RU2504550C2 |
| FGF21 DERIVATIVES AND USE THEREOF | 2015 |
|
RU2729011C2 |
| POLYPEPTIDES | 2012 |
|
RU2669999C2 |
| ACYLATED GLP-1 COMPOUNDS | 2006 |
|
RU2434019C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
| SOLID COMPOSITIONS CONTAINING AGONIST TO GLP AND SALT OF N-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 2011 |
|
RU2600440C2 |
